following an abbreviated submission:
formoterol fumarate dihydrate / glycopyrronium / budesonide (Trixeo® Aerosphere) is accepted for restricted use within NHSScotland.
Indication under review: maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist.
SMC restriction: in patients with severe COPD (forced expiratory volume in one second [FEV1] less than 50% predicted normal).
Formoterol fumarate dihydrate / glycopyrronium / budesonide (Trixeo® Aerosphere) offers an additional treatment choice of long-acting beta2-agonist (LABA), long-acting muscarinic antagonist (LAMA) and inhaled corticosteroid (ICS) in a single inhaler.
Download detailed advice731KB (PDF)
Medicine details
- Medicine name:
- formoterol fumarate dihydrate/glycopyrronium/budesonide (Trixeo Aerosphere)
- SMC ID:
- SMC2321
- Indication:
Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long‑acting beta2‑agonist or combination of a long-acting beta2‑agonist and a long‑acting muscarinic antagonist.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 08 February 2021